# BPC-157: a rat literature with a human reputation > BPC-157: the human trials that do not exist - Research Peptide Fundamentals research peptides - Checked Peptides — A gap-first summary of BPC-157 among Research Peptide Fundamentals research peptides: a large rodent literature, three small human pilot studies, no human pharmacokinetics, and no independent replication of the foundational work. **01 / THE SPECIES GAP** Consistent, striking healing results in rodents; three small pilot studies in people; and no controlled human trial of any injury indication. This page names what is missing rather than what is promised. ## The short version BPC-157 is a synthetic chain of fifteen amino acids, copied from part of a protein found in human gastric juice. In rats it does genuinely striking things. It speeds the healing of a fully cut Achilles tendon across biomechanical, functional and microscopic measures [6], and it shrinks stomach ulcers, with an ulcer-formation inhibition ratio of 45.7 to 65.6 percent at the higher amounts tested [5]. That animal record is why anyone is talking about it. The gap underneath it is the size of a canyon. A 2025 narrative review states that only three pilot studies have examined BPC-157 in humans and that rigorous, large-scale trials are lacking [2]. The one human safety report summarised here enrolled two adults [1]. No controlled human trial has ever measured whether BPC-157 heals a tendon, an ulcer, or anything else in a person. Its basic pharmacology has the same shape. The only formal study of how the body absorbs, distributes and clears it was done in rats and beagle dogs [3]. Nobody has published a half-life for BPC-157 in a human being. So the honest summary is short: a large and coherent animal literature, an almost empty human one, and a set of popular claims that run well ahead of both. ## What it is BPC-157 stands for Body Protection Compound 157. It is a stable gastric pentadecapeptide, which unpacks to: a fifteen-amino-acid peptide, derived from a gastric protein, that does not fall apart in stomach acid. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and its molecular formula is C62H98N16O22. In older literature and on supplier listings it also appears as pentadecapeptide BPC 157, PL 14736, PLD-116 or PL-10. Its regulatory position is unambiguous and is part of the evidence picture rather than separate from it. BPC-157 is not an approved medicine anywhere. In 2023 the US Food and Drug Administration placed it in a category of bulk substances it identified as not eligible for pharmacy compounding under section 503A, pending further evaluation. The World Anti-Doping Agency prohibits it in sport at all times under its category for non-approved substances. Material sold under the name is offered for laboratory research use only and is not intended for human consumption. That matters for reading the literature, not just for compliance. Because the compound moves through non-regulated channels, the identity, purity and actual content of any given vial are unverified outside a formal study, a point a 2025 review makes explicitly when it recommends treating BPC-157 as investigational [2]. ## How it works, as far as anyone can tell The plainest available description is that BPC-157 appears to encourage the growth of new blood supply into damaged tissue. Healing is limited by plumbing more often than people expect: a tendon or an ulcer bed that cannot get blood cannot rebuild. Most of the mechanism work points at that step. The best-characterised pathway runs through VEGFR2, a receptor on the cells that line blood vessels. A 2017 study found that BPC-157 both increases the amount of VEGFR2 present and promotes its internalisation, switching on the downstream VEGFR2-Akt-eNOS signalling chain that ends in nitric oxide production. The same work reported increased vessel density in a chick membrane model and in cultured human vascular endothelial cells, and faster restoration of blood flow in a rat hind limb with a blocked artery; the effects disappeared when the cells were prevented from internalising the receptor [4]. Several other routes are reported alongside it: the FAK-paxillin complex, which governs how cells crawl into a wound; sensitisation of the growth-hormone receptor in tendon cells; and modulation of the nitric oxide system. A 2016 review positions BPC-157 as a mediator on the brain-gut axis that alters nigrostriatal serotonin release and dopaminergic signalling and engages the Egr-1, NAB2, FAK-paxillin and JAK-2 pathways [7]. The gap in this section is a specific one and it is easy to miss. Every mechanism above was demonstrated in a rodent, a chick membrane, or cells in a dish. None of it has been observed in a living human. A mechanism is a hypothesis about why something might work; it is not evidence that it does. ## What the research shows, and what each study leaves open *Rat gastric ulcers, 2004.* BPC 157 reduced ulcer area and accelerated healing in Wistar rats, with an ulcer-formation inhibition ratio of 45.7 to 65.6 percent at higher amounts and faster rebuilding of glandular epithelium and granulation tissue. Intramuscular delivery outperformed delivery straight into the stomach [5]. **Left open:** the species, and whether the route difference holds in an animal with human gut physiology. *Rat Achilles tendon, 2003.* A fully transected rat Achilles tendon healed faster on biomechanical, functional, microscopic and macroscopic measures, with better collagen organisation than untreated controls, and rat tendon cells grew out faster in culture [6]. **Left open:** everything about humans. This is the single most-quoted result in the compound's popular literature and it has no human counterpart. *Blood-vessel mechanism, 2017.* The VEGFR2-Akt-eNOS pathway work described above, across a chick chorioallantoic membrane, a rat hind-limb ischaemia model and human endothelial cells in culture [4]. **Left open:** whether the same pathway is engaged in an intact human, and what a strongly pro-angiogenic agent does over years rather than days. *Pharmacokinetics, 2022.* The first formal characterisation of absorption, distribution, metabolism and excretion found linear kinetics, an elimination half-life under 30 minutes, intramuscular bioavailability of roughly 14 to 19 percent in rats and roughly 45 to 51 percent in dogs, rapid breakdown into small fragments that rejoin normal amino-acid metabolism, and excretion in urine and bile [3]. **Left open:** the human number. Note also that the two animal species disagree by about threefold on bioavailability, which is precisely the situation in which extrapolating to a third species is unsafe. *Human safety pilot, 2025.* Intravenous BPC-157 at up to 20 mg was given to two healthy adults, a 58-year-old man and a 68-year-old woman. It was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers [1]. **Left open:** almost everything. Two participants, no control group, no efficacy endpoint, and a single intravenous exposure rather than the repeated subcutaneous use the compound is actually put to. *The 2025 review, 2025.* A narrative review of BPC-157 for musculoskeletal healing concluded that despite broad preclinical support, human data are extremely limited, rigorous large-scale trials are lacking, and the compound should be considered investigational and approached with caution given the regulatory position and non-regulated availability [2]. **Left open:** this is the field describing its own hole. It is the most useful citation on this page. *Brain-gut axis review, 2016.* A synthesis positioning BPC 157 within Robert's cytoprotection framework, reporting modulation of serotonergic and dopaminergic systems and involvement of Egr-1, NAB2, FAK-paxillin and JAK-2 [7]. **Left open:** it is a review of rodent central-nervous-system and gastrointestinal work, and inherits every limit of the studies under it. One structural gap sits across all of the above. A large share of the foundational literature was produced by a single research group and its collaborators, and newer reviewers flag this explicitly [2]. Independent replication is the mechanism by which science removes the influence of a single laboratory's methods and assumptions. For BPC-157 it has largely not happened. ## Reported effects, cautions and safety What follows is anecdotal, not clinical evidence. It is drawn from research-use forums, clinic write-ups and published summaries of online reports, carries no verified product identity, and is recorded here because it describes what people say rather than what has been demonstrated. No amounts are reported alongside it. The most common reason people in these communities describe trying BPC-157 is stubborn tendon, ligament and joint injury, and faster recovery from it is very commonly reported, often within the first one to three weeks. Reduced joint stiffness and easier painful movement are frequently reported. So are improvements in digestive symptoms, which people connect to the compound's gastric origin, with less bloating, cramping and urgency described in the first week or two. Faster closing of minor skin wounds, better sleep or steadier mood, and a general impression of reduced inflammation are all reported occasionally, and the last of these is essentially impossible to separate from placebo. On the unwanted side, injection-site redness, stinging or a small bump is very commonly reported and described as fading within a day. Nausea or mild stomach upset is frequently reported, more often with oral or sublingual products than with injections. Fatigue in the first week, headache, brief dizziness on standing, and transient flushing or warmth are all reported occasionally, and the flushing is usually attributed by the people reporting it to the compound's effects on blood vessels. Palpitations are rarely reported, and commentators treat a persistent fast heartbeat, chest pain or a marked blood-pressure change as a reason to stop and seek medical assessment. The documented cautions are these, and most of them are gaps rather than findings. - **The human evidence is extremely thin.** Almost everything known comes from rodents; as of 2025 reviews only a handful of small, uncontrolled human pilot reports exist and large controlled trials are lacking [1][2]. The real balance of benefit and risk in people is unknown rather than favourable. - **Independent replication is limited.** A large share of the foundational work comes from one group [2], so the consistency of the literature may partly reflect the consistency of a single laboratory. - **Product identity is unverified.** It is not an approved medicine and is distributed through non-regulated channels, so what is in a given vial is not established outside formal research [2]. - **The pro-angiogenic activity raises a theoretical concern in cancer.** Tumours also depend on new blood vessels, and BPC-157's repair effects are tied to the VEGFR2 pathway and the nitric oxide system [4]. This is mechanism-based reasoning; no human study has examined it. - **A possible interaction with serotonin-affecting medicines.** Rodent work reports changes in brain serotonin activity [7], which raises a theoretical concern about combining it with serotonin-raising medicines. No human interaction study exists. - **It nudges growth signalling, and no long-term human data exist.** Sensitisation of the growth-hormone receptor in tendon cells is part of the proposed repair mechanism, and any agent that pushes growth pathways leaves an open question about long-term or unwanted tissue growth that nothing in the literature currently answers. - **It is banned in sport at all times** by the World Anti-Doping Agency, which is a practical consequence rather than a medical one, and it has not been studied in pregnancy, breastfeeding or children. ## Where it fits in the gap register BPC-157 is the clean case of a species gap, and it is the reason this desk exists. Nothing about the animal literature is weak; it is broad, internally consistent and mechanistically coherent. The problem is that it stops at the edge of the human body and the popular account of the compound does not. Set against the others here, the contrast is sharp. [Retatrutide](/retatrutide) is unapproved and yet has thousands of participant-weeks of controlled human data behind it. [PT-141](/pt-141) has an approval and a 52-week safety extension. BPC-157 has a two-person intravenous pilot [1] and a review saying the trials have not been done [2]. Three of the four compounds on this desk are arguing about how good their human evidence is; this one is arguing about whether it has any. The most useful single question a reader can carry away from this page is the pharmacokinetic one. Dosing schedules circulating in research-use communities are arithmetic performed on an animal half-life measured at under 30 minutes, in two species that disagree threefold about how much of an intramuscular amount even reaches the bloodstream [3]. Until someone measures that in a person, every schedule built on it is a guess wearing a number. See [the comparison page](/compare) for how that failure mode differs from the other three. ![BPC-157 research illustration - abstract vascular repair motif in slate and cyan](/images/bpc-157.webp) --- Checked Peptides is an independent reading desk that keeps a written record of what peptide research has not established yet: it sells nothing, prescribes nothing, and treats a missing study as a fact worth printing.